Ipilimumab and valproic acid for melanoma – pro
Only phase I data about this combination is availabe (Baumans et al). A retrospective subgroup analysis of patients included in the seminal EORTC/NCIC 26981-22981 trial that underwent valproic acid treatment at inclusion showed a significantly better outcome than patients that did not undergo any antiepileptic treatment (HR = 0.67, 95% CI = 0.49-0.93) or those treated with an enzyme-inducing antiepileptic agent (HR = 0.69, 95% CI = 0.53-0.90), although these patients showed more hematologic adverse events[47]. These findings could not be confirmed in the phase III Cilengitide trial.
Julie Bauman et al, A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers, Translational Oncology Volume 7, Issue 3, June 2014, Pages 349–354
Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011;77:1156–1164.